Deciphera Pharmaceuticals, Inc.

$16.41 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering medicines to patients for the treatment of cancer. The Company has developed a switch-control kinase inhibitor platform in kinase biology to execute its strategy to develop a broad portfolio of medicines. The Company has one approved drug, QINLOCK, which is a switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). In addition, the Company is developing three clinical-stage drug candidates, which includes Vimseltinib (DCC-3014) - colony stimulating factor 1 receptor (CSF1R) Kinase Inhibition for Tenosynovial Giant Cell Tumor (TGCT), Rebastinib - TEK tyrosine kinase (TIE2) Kinase Inhibition for advanced or Metastatic Solid Tumors, and DCC-3116 - ULK Kinase Inhibition for Mutant RAS/RAF Cancers.

Stock Analysis

last close $16.41
1-mo return 23.7%
3-mo return 64.8%
avg daily vol. 796.93T
52-week high 37.99
52-week low 6.51
market cap. $1.1B
forward pe -
annual div. -
roe -60.6%
ltg forecast -
dividend yield -
annual rev. $109M
inst own. 64.3%
baraka

Subscribe now for daily local and international financial news

Subscribe